Related Experiment Video
Updated: Apr 21, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1
1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, People's Republic of China.
Abstract:
Cisplatin resistance presents a major challenge in the successful treatment of breast cancer, and its mechanism has not been documented well. In this study, to determine the relationship between chemotherapy resistance and microRNA (miRNA) expression during the development of cisplatin resistance in breast cancer, we used microRNA microarrays analysis successfully identified 19 miRNAs that were either overexpressed or underexpressed (8 upregulated and 11 downregulated) in the MCF-7 cell line and its cisplatin-resistant variant MCF-7/DDP. Among them, the miR-218 was most downregulated in cisplatin-resistant cell lines and identified that breast cancer 1 (BRCA1) was the cellular targets of miR-218. In vivo assay also demonstrated that restoring miR-218 expression in MCF-7/DDP cell line could sensitize cells against cisplatin, thereby increasing cisplatin-mediated tumor cell apoptosis and reducing DNA repair. Kaplan-Meier survival analysis indicated that patients with breast cancer display high levels of miR-218 and low levels of BRCA1 expression; these patients may gain the greatest benefits in terms of increased survival when treated with cisplatin. All of these results indicated that miR-218 has a significant function in the development of cisplatin resistance in breast cancer. Restoring miR-218 expression may constitute a novel therapeutic approach by which to increase cisplatin sensitivity in breast cancer.
Insights
MicroRNA-218 (miR-218) downregulation is linked to cisplatin resistance in breast cancer. Restoring miR-218 may re-sensitize tumors to chemotherapy, offering a new treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cisplatin resistance is a significant obstacle in breast cancer treatment.
- The underlying mechanisms of cisplatin resistance, particularly involving microRNAs, require further elucidation.
Purpose of the Study:
- To investigate the role of microRNA expression in the development of cisplatin resistance in breast cancer.
- To identify specific microRNAs and their targets involved in mediating cisplatin resistance.
Main Methods:
- MicroRNA microarrays were used to compare miRNA expression between MCF-7 breast cancer cells and their cisplatin-resistant variant (MCF-7/DDP).
- In vivo assays were conducted to assess the effect of restoring miR-218 expression on cisplatin sensitivity.
- Kaplan-Meier survival analysis was performed on patient data correlating miR-218 and BRCA1 levels with cisplatin treatment outcomes.
Main Results:
- MicroRNA microarray analysis identified 19 differentially expressed miRNAs, with miR-218 being significantly downregulated in cisplatin-resistant cells.
- Breast cancer 1 (BRCA1) was identified as a direct target of miR-218.
- Restoring miR-218 expression in resistant cells increased sensitivity to cisplatin, promoted apoptosis, and reduced DNA repair.
- High miR-218 and low BRCA1 expression correlated with better survival outcomes in breast cancer patients treated with cisplatin.
Conclusions:
- miR-218 plays a crucial role in the development of cisplatin resistance in breast cancer.
- Targeting miR-218 or its pathway represents a potential therapeutic strategy to overcome cisplatin resistance and improve patient survival.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22MicroRNAs
01:22MicroRNAs